Skip to content

Study · Non-randomized trial · n = 17 · 1986

6 results

DDAVP and urine osmolality in refractory enuresis.

Dimson SB

Archives of disease in childhood1 Nov 1986Cited by 35 (Europe PMC)

PMID3539030 (opens in a new tab)PMCIDPMC1778127 (opens in a new tab)DOI10.1136/adc.61.11.1104 (opens in a new tab)PepBankPUB-03539030
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with refractory enuresis, desmopressin significantly reduced wet nights versus placebo.

    In plain wordsIn children with refractory enuresis, desmopressin reduced wet nights versus placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseWet nights
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in the number of wet nights.
    1 context sentence
    Summary · context
    A double blind crossover trial of 20 micrograms intranasal 1-deamino-8-d-arginine vasopressin (DDAVP) versus placebo was carried out in 17 children with intractable enuresis aged between 6 and 13 years who had failed to respond to drugs and an enuresis alarm.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with refractory enuresis, seven children (41%) were cured or considerably improved with desmopressin, with evidence against a placebo effect.

    In plain wordsIn children with refractory enuresis, desmopressin produced cure or considerable improvement in seven children, with evidence against a placebo effect.

    Peptide
    Desmopressin
    Outcome
    IncreaseCure or considerable improvement
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Measurements

    Children cured or considerably improved
    7 children
    DDAVP crossover, refractory enuresis
    Proportion cured or considerably improved
    41%
    DDAVP crossover, refractory enuresis

    Source sentences

    Summary
    Seven children (41%) were cured or showed considerable improvement, with strong evidence against any placebo effect.
    1 context sentence
    Summary · context
    A double blind crossover trial of 20 micrograms intranasal 1-deamino-8-d-arginine vasopressin (DDAVP) versus placebo was carried out in 17 children with intractable enuresis aged between 6 and 13 years who had failed to respond to drugs and an enuresis alarm.
  3. 03HumanNon-randomized trialEfficacy outcome

    In refractory enuresis children with normal overnight urine osmolality, desmopressin produced two successes among six children.

    In plain wordsIn children with refractory enuresis and normal overnight urine osmolality, desmopressin produced two successes among six children.

    Peptide
    Desmopressin
    Outcome
    Not applicableSuccess with normal baseline urine osmolality
    Study

    n = 6

    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    20 microgramsAs given in this study (human).

    Measurements

    Successes
    2 children
    normal overnight urine osmolality before treatment

    Source sentences

    Summary
    Six of them had previously normal overnight urine osmolalities with only two successes, but of the six who had nocturnal diuresis before treatment, five became dry, suggesting that DDAVP acts largely by anti-diuresis and might be most useful in children with nocturnal polyuria.
    1 context sentence
    Summary · context
    A further 12 children with equally refractory enuresis were given 20 micrograms of the active drug to take during their school journeys or holidays.
  4. 04HumanNon-randomized trialEfficacy outcome

    In refractory enuresis children with nocturnal diuresis, five of six became dry after desmopressin.

    In plain wordsIn children with refractory enuresis and nocturnal diuresis, five of six became dry after desmopressin.

    Peptide
    Desmopressin
    Outcome
    Not applicableDryness with baseline nocturnal diuresis
    Study

    n = 6

    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    20 microgramsAs given in this study (human).

    Measurements

    Children who became dry
    5 children
    nocturnal diuresis before treatment

    Source sentences

    Summary
    Six of them had previously normal overnight urine osmolalities with only two successes, but of the six who had nocturnal diuresis before treatment, five became dry, suggesting that DDAVP acts largely by anti-diuresis and might be most useful in children with nocturnal polyuria.
    1 context sentence
    Summary · context
    A further 12 children with equally refractory enuresis were given 20 micrograms of the active drug to take during their school journeys or holidays.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with refractory enuresis, response to desmopressin was best in children aged 10 years or over and when urine osmolality after desmopressin reached beyond 1000 mmol/kg or was already at that concentration.

    In plain wordsFor persistent bedwetting, desmopressin worked best at ages 10 or older and with urine already concentrated or concentrated after dosing.

    Peptide
    Desmopressin
    Outcome
    Not applicableResponse by age and urine osmolality
    Study

    n: not reported in source

    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Measurements

    Age
    ≥ 10 years
    best response, children aged 10 years or over
    Urine osmolality
    ≥ 1000 mmol/kg
    after DDAVP reached beyond this value or was already at this concentration

    Source sentences

    Summary
    The best response was seen in children aged 10 years or over and if urine osmolality after DDAVP reached beyond 1000 mmol/kg or was already at this concentration.
    1 context sentence
    Summary · context
    A double blind crossover trial of 20 micrograms intranasal 1-deamino-8-d-arginine vasopressin (DDAVP) versus placebo was carried out in 17 children with intractable enuresis aged between 6 and 13 years who had failed to respond to drugs and an enuresis alarm.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children with refractory enuresis, the overnight urine osmolality rise after desmopressin was unpredictable but correlated with improved nocturnal diuresis.

    In plain wordsIn children with refractory enuresis, urine osmolality changes after desmopressin correlated with improvement in nocturnal diuresis.

    Peptide
    Desmopressin
    Outcome
    Not applicableUrine osmolality and clinical response
    Study

    n: not reported in source

    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Measurements

    Children with clinical improvement in nocturnal diuresis
    8 children
    correlated with overnight urine osmolality rise

    Source sentences

    Summary
    The degree of overnight rise in urine osmolality after treatment with DDAVP was not predictable but correlated well with the clinical improvement in nocturnal diuresis present in eight of the children.
    1 context sentence
    Summary · context
    A double blind crossover trial of 20 micrograms intranasal 1-deamino-8-d-arginine vasopressin (DDAVP) versus placebo was carried out in 17 children with intractable enuresis aged between 6 and 13 years who had failed to respond to drugs and an enuresis alarm.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.